Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study (DOI:10.1016/j.schres.2009.02.017)

Schizophrenia Research

Volumn 113, Issue 1, 2009, Pages 112-121

  Sacchetti, Emilio ^a,b,c   Galluzzo, Alessandro ^a,b   Valsecchi, Paolo ^a,b   Romeo, Fabio ^d   Gorini, Barbara ^d   Warrington, Lewis ^d  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Brescia University School of Medicine and Brescia Spedali Civili ^*  (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d PFIZER INC   (United States)

Author keywords

Clozapine; Tolerability; Treatment resistance; Ziprasidone

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; ZIPRASIDONE;

ADULT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; ERRATUM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERSALIVATION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SHORT COURSE THERAPY; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; THERAPY RESISTANCE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPIDS; MALE; METABOLOME; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; THIAZOLES; TREATMENT OUTCOME;

EID: 67649842418     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.05.002     Document Type: Erratum

References (70)

1. Addington D., Addington J., and Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 3 (1990) 247-251
2. Addington D., Addington J., Maticka-Tyndale E., and Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr. Res. 6 (1992) 201-208
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Fourth Edition (1994), American Psychiatric Association, Washington, DC
4. Arranz B., Rosel P., Ramirez N., Duenas R., Fernandez P., Sanchez J.M., Navarro M.A., and San L. Insulin resistance and increased leptin concentration in noncompliant schizophrenia patient but not in antipsychotic-naïve first-episode schizophrenia patients. J. Clin. Psychiatry 65 (2004) 1335-1342
5. Awad A.G., and Hogan T.P. Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr. Scand., Suppl. 380 (1994) 27-32
6. Azorin J.M., Spiegel R., Remington G., Vanelle J.M., Pere J.J., Giguere M., and Bourdeix I. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am. J. Psychiatry 158 (2001) 1305-1313
7. Baptista T., ElFakih Y., Uzcátegui E., Sandia I., Tálamo E., Araujo de Baptista E., and Beaulieu S. Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 22 6 (2008) 477-495
8. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154 (1989) 672-676
9. Bitter I., Dossenbach M.R., Brook S., Feldman P.D., Metcalfe S., Gagiano C.A., Furedi J., Bartko G., Janka Z., Banki C.M., Kovacs G., and Breier A. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog. Neuro-psychopharmacol. Biol. Psychiatry 28 (2004) 173-180
10. Bondolfi G., Dufour H., Patris M., May J.P., Billeter U., Eap C.B., Baumann P., and Risperidone Study Group. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am. J. Psychiatry 155 (1998) 499-504
11. Breier A.F., Malhotra A.K., Su T.P., Pinals D.A., Elman I., Adler C.M., Lafargue R.T., Clifton A., and Pickar D. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am. J. Psychiatry 156 (1999) 294-298
12. Chakos M., Lieberman J., Hoffman E., Bradford D., and Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry 158 (2001) 518-526
13. Chuang H.T., Mansell C., and Patten S.B. Lifestyle characteristics of psychiatric outpatients. Can. J. Psychiatry 53 4 (2008) 260-266
14. Conley R.R., and Kelly D.L. Management of treatment resistance in schizophrenia. Biol. Psychiatry 50 (2001) 898-911
15. Conley R.R., Kelly D.L., Richardson C.M., Tamminga C.A., and Carpenter Jr. W.T. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J. Clin. Psychopharmacol. 23 (2003) 668-671
16. De Hert M., Schreurs V., Sweers K., Van Eyck D., Hanssens L., Šinko S., Wampers M., Scheen A., Peuskens J., and van Winkel R. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr. Res. 101 (2008) 295-303
17. Elkis H. Treatment-resistant schizophrenia. Psychiatr. Clin. North Am. 30 (2007) 511-533
18. Essock S.M., Hargreaves W.A., Dohm F.A., Goethe J., Carver L., and Hipshman L. Clozapine eligibility among state hospital patients. Schizophr. Bull. 22 (1996) 15-25
19. Felker B., Yazel J.J., and Short D. Mortality and medical comorbidity among psychiatric patients: a review. Psychiatr. Serv. 47 (1996) 1356-1363
20. Gough S.C., and O'Donovan M.C. Clustering of metabolic comorbidity in schizophrenia: a generic contribution?. J. Psychopharmacol. 19 suppl 6 (2005) 47-55
21. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept of Health, Education and Welfare (1976), National Institute of Mental Health, Washington, DC 76-338
22. Harvey P.D., Sacchetti E., Galluzzo A., Romeo F., Gorini B., Bilder R.M., and Loebel A.D. A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. Schizophr. Res. 105 (2008) 138-143
23. Haupt D.W. Differential metabolic effect of antipsychotic treatments. Eur. Neuropsychopharmacol. 16 supp 3 (2006) s149-s155
24. Henderson D.C. Schizophrenia and comorbid metabolic disorders. J. Clin. Psychiatry 66 suppl.6 (2005) 11-20
25. Henderson D.C., Nguyen D.D., Copeland P.M., Hayden D.L., Borba C.P., Louie P.M., Freudenreich O., Evins E., Cather C., and Goff D.C. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-years naturalistic study. J. Clin. Psychiatry 66 (2005) 1116-1121
26. Kane J.M. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials. J. Clin. Psychiatry 64 Suppl 19 (2003) 19-25
27. Kane J.M., Khanna S., Rajadhyaksha S., and Giller E. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int. Clin. Psychopharmacol. 21 (2006) 21-28
28. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
29. Kay S.R., Opler L.A., and Lindenmayer J.P. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 23 (1988) 99-110
30. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br. J. Psychiatry 184 suppl.47 (2004) s64-s66
31. Koranyi E.K. Morbidity and rate of undiagnosed physical illnesses in a psychiatric clinic population. Arch. Gen. Psychiatry 36 (1979) 414-419
32. Lamberti J.S., Olson D., Crilly J.F., Olivares T., Williams G.C., Tu X., Tang W., Wiener K., Dvorin S., and Dietz M.B. Prevalence of the metabolic syndrome among patients receiving clozapine. Am. J. Psychiatry 163 (2006) 1273-1276
33. Lerner V., Libov I., Kotler M., and Strous R.D. Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog. Neuro-psychopharmacol. Biol. Psychiatry 28 (2004) 89-98
34. Leucht S., Burkard T., Henderson J., Maj M., and Sartorius N. Physical illness and schizophrenia: a review of literature. Acta Psychiatr. Scand. 116 (2007) 317-333
35. Leucht S., Corves C., Arbter D., Engel R.R., Li C., and Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373 (2009) 31-41
36. Lieberman J.A., Stroup T.S., McEvoy J.P., Scwartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Effectiveness of antipsychotic drugs in patients with schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
37. Lin H.C., Chen C.S., Liu T.C., Tsai S.-Y., and Lee H.-C. Lack of care for diabetes among schizophrenia patients. Schizophr. Res. 89 (2007) 353-354
38. Lindenmayer J.P. Treatment refractory schizophrenia. Psychiatr. Q. 71 (2000) 373-384
39. Lindenmayer J.P., Czobor P., Volavka J., Citrome L., Sheitman B., McEvoy J.P., Cooper T.B., Chakos M., and Lieberman J.A. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am. J. Psychiatry 160 (2003) 290-296
40. Loebel A.D., Khanna S., Rajadhyakska S., Siu C.O., Giller E., and Potkin S.G. Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study. J. Clin. Psychiatry 68 (2007) 1333-1338
41. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Casey D.E., Davis J.M., Kane J.M., Lieberman J.A., Schooler N.R., Covel N., Stroup S., Weissman E.M., Wirshing D.A., Hall C.S., Pogach L., Pi-Sunyer X., Bigger J.T., Friedman A., Kleinberg D., Yevich S.J., Davis B., and Shon S. Physical health monitoring of patients with schizophrenia. Am. J. Psychiatry 161 (2004) 1334-1349
42. McCreadie R.G., and Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br. J. Psychiatry 183 (2003) 534-539
43. McEvoy J.P. The cost of schizophrenia. J. Clin. Psychiatry 68 suppl 14 (2007) 4-7
44. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., Meltzer H.Y., Hsiao J., Stroup T.S., and Lieberman J.A. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80 (2005) 19-32
45. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., and Hsiao J.K. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 163 (2006) 600-610
46. Meyer J.M., Davis V.G., Goff D.C., McEvoy J.P., Nasrallah H.A., Davis S.M., Rosenheck R.A., Daumit G.L., Hsiao J., Swartz M.S., Stroup T.S., and Lieberman J.A. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1. Schizophr. Res. 101 (2008) 273-286
47. Meyer-Lindenberg A., Gruppe H., Bauer U., Lis S., Krieger S., and Gallhofer B. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry 30 (1997) 35-42
48. Millar H. Management of physical health in schizophrenia: a stepping stone to treatment success. Eur. Neuropsychopharmacol. 18 (2008) s121-s128
49. Moncrieff J. Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. Br. J. Psychiatry 183 (2003) 161-166
50. Montes J.M., Rodriguez J.L., Balbo E., Sopelana P., Martin E., Soto J.A., Delgado J.F., Diez T., and Villardaga I. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 31 (2007) 383-388
51. Nasrallah H.A. Atypical antipsychotic-induced metabolic side effect: insights from receptor-binding profiles. Mol. Psychiatry 13 (2008) 27-35
52. Newcomer J.W. Second-generation (atypical) antispychotics and metabolic effects. A comprehensive literature review. CNS Drugs 19 suppl.1 (2005) 1-93
53. Newcomer J.W. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J. Clin. Psychiatry 68 suppl 1 (2007) 20-27
54. Revicki D.A. The new atypical antipsychotics: a review of pharmacoeconomic studies. Expert Opin. Pharmacother. 1 (2000) 249-260
55. Ryan M.C., Collins P., and Thakore J.H. Impaired fasting glucose and elevation of cortisol elevation in drug-naïve first episode schizophrenia. Am. J. Psychiatry 160 (2003) 284-289
56. Ryan M.C., Flanagan S., Kinsella U., Keeling F., and Thakore J.H. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naïve patients with schizophrenia. Life Sci. 74 (2004) 1999-2008
57. Sacchetti E., Panariello A., Regini C., and Valsecchi P. Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial. Schizophr. Res. 69 (2004) 325-331
58. Sacchetti E., Valsecchi P., Parrinello G., and QUERISOLA Group. A randomized, flexible-dose, quasi naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial. Schizophr. Res. 98 (2008) 55-65
59. Sengupta S., Parrilla-Escobar M.A., Klink R., Fathalli F., Ng K.Y., Stip E., Baptista T., Malla A., and Joober R. Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls?. Schizophr. Res. 102 (2008) 329-336
60. Sharif Z. Side effects as influencers of treatment outcome. J. Clin. Psychiatry 69 suppl 3 (2008) 38-43
61. Simpson G.M., and Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand., Suppl. 212 (1970) 11-19
62. Simpson G.M., Glick I.D., Weiden P.J., Romano S.J., and Siu C.O. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am. J. Psychiatry 161 (2004) 1837-1847
63. Simpson G.M., Weiden P., Pigott T., Murray S., Siu C.O., and Romano S.J. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am. J. Psychiatry 162 (2005) 1535-1538
64. Spelman L.M., Walsh P.I., Sharifi N., Collins P., and Thakore J.H. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet. Med. 24 (2007) 481-485
65. Taylor D.M., and Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics. J. Psychopharmacol. 14 (2000) 409-418
66. Thakore J.H. Metabolic disturbance in first-episode. Br. J. Psychiatry 184 suppl.47 (2004) s76-s79
67. Tollefson G.D., Birkett M.A., Kiesler G.M., and Wood A.J. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol. Psychiatry 49 (2001) 52-63
68. Volavka J., Czobor P., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J.P., Cooper T.B., Chakos M., and Lieberman J.A. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry 159 (2002) 255-262
69. Weiden P.J., Newcomer J.W., Loebel A.D., Yang R., and Lebovitz H.E. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 33 (2008) 985-994
70. Ziegenbein M., Kropp S., and Kuenzel H.E. Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. Clin. Neuropharmacol. 28 (2005) 220-224